On April 10, Geron announced that its licensing partner, Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson ( JNJ 1.16% ), had completed its second internal data review of the IMerge and IMbark trials that respectively pertain to imetelstat as a treatment for myelodysplastic syndromes and myelofibrosis. As you can probably surmise from the move higher, things are moving along nicely after a bit of a hiccup following the first internal data review.